Sector News

GlaxoSmithKline consumer hiving off Canada plant with 400 workers to Taiwan CDMO

March 11, 2020
Life sciences

The recent GlaxoSmithKline and Pfizer consumer joint venture intends to sell off £1 billion worth of assets to raise some cash for operations and is losing no time in doing so.

A plant in Canada with 400 employees is now on the front line of that effort while giving a Taiwan-based CDMO a North American manufacturing foothold.

GSK and Bora Pharmaceuticals announced the deal Monday, saying they expect to close the sale of the consumer products plant by year-end. The 400 plant employees are being offered positions with Bora, while GSK employees on the commercial side housed in offices at the facility will transfer to other GSK sites.

Financial terms of the deal were not disclosed, but the two said that Bora will manufacture for GSK the more than 50 products produced at the plant for at least five years.

“We are excited to announce today the next phase of our expansion into North America with the acquisition of this world-class facility and we look forward to welcoming the Mississauga manufacturing employees, whom we view as the most significant asset in this transaction, into our business,” Bora CEO Bobby Sheng said in a statement. “The Mississauga-based facility is ideally suited with our intention to grow our technical capabilities and scale in the global contract development and manufacturing organization (CDMO) marketplace.”

The acquisition will nearly double the employee size of the CDMO, which currently has 470 workers at two manufacturing sites in Taiwan. That includes a 400,000-square-foot plant it acquired from Impax Laboratories in 2018. Bora last year opened an office in Delaware.

The sale to Bora comes just three weeks after the JV said it will close a GSK OTC plant in Pennsylvania with 260 employees by the end of 2021 and consolidate production into a facility in Guayama, Puerto Rico. The GSK plant makes vitamin C supplement Emergen-C.

The plant sales are part of a much larger plan in which GSK and Pfizer intend to spin off the joint venture within three years and list it as standalone company on the U.K. exchange as GSK Consumer Healthcare. That will leave GSK to focus on medicines and vaccines.

By Eric Palmer

Source: Fierce Pharma

comments closed

Related News

September 25, 2022

Rise of the machines: Novo Nordisk pledges $200M to create first quantum computer for life sciences

Life sciences

Big Pharma has long seen the potential for AI and machine learning to accelerate drug development. But Novo Nordisk is going a step further by channeling $200 million toward the creation of a computer that will outrun anything in existence.

September 25, 2022

Mount Sinai AI uncovers new brain analysis method to predict dementia, Alzheimer’s disease

Life sciences

Current methods for diagnosing Alzheimer’s disease rely on a complex combination of self- and caregiver-reported symptoms, a physical examination and either a PET scan or a spinal tap to look for evidence of amyloid plaque build-ups in the brain. But a new artificial intelligence-based method may make the diagnostic process a much more objective one.

September 25, 2022

New AstraZeneca-backed report finds big money behind diverse owners and entrepreneurs in Europe

Life sciences

There is lots of talk about diversity and inclusion in business, including in pharma and medtech. A new report by the Open Political Economy Network (OPEN), a think tank focusing on migration and diversity, released its “Minority Businesses Matter: Europe” report highlighting the successes and challenges of ethnic minority-owned businesses in Europe.